Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia

Abstract Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these patients also have coagulopathy and thrombocytopenia of varying severity. Recombinant factor VIIa is a FDA‐approved agent for management of bleeding in hemophilia patients with inhibitors. Use...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Amir M. Ansari, Adam Khorasanchi, Armaghan Faghihimehr, Amir Toor
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
R
Acceso en línea:https://doaj.org/article/8c32758b797d4d20b4dd364c0121569e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!